With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Understanding and inhibiting mechanisms of metastatic spread in osteosarcoma||University of California San Francisco / Alejandro Sweet-Cordero, MD||Crazy 8 Awards||2022||California|
|Isoform-specific TNC-redirected T cell Therapy for DIPG||St. Jude Children's Research Hospital / Stephen Gottschalk, MD and Giedre Krenciute, PhD||Innovation Grants||2022||Tennessee|
|Using Chemical Genetics to Define the Precise Role of RUNX1 in Transcription and Beyond||Albert Einstein College of Medicine / Kristy Stengel||RUNX1 Early Career Investigator Grants||2022||New York|
|Targeting the biological underpinnings of pulmonary metastasis in osteosarcoma||Dana-Farber Cancer Institute / Rani George, MD/PhD||Crazy 8 Awards||2022||Massachusetts|
|Delivering on the Promise of Germline Genetic Testing for RUNX1 Variants||University of Washington, Seattle / Abbye McEwen, MD, PhD||RUNX1 Early Career Investigator Grants||2022||Washington|
|Developmental origins of leukemia in Down Syndrome||University of Rochester / James Palis, MD & Laurie Steiner, MD||Innovation Grants||2022||New York|
|Enhancing TKI Therapy in Ph-Like Leukemia||The Regents of the University of California, Irvine / David Fruman, PhD||Reach Grants||2022||California|
|Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG||The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD||Reach Grants||2022||Michigan|
|Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations||The Regents of the University of Michigan / Jolanta Grembecka, PhD||Reach Grants||2022||Michigan|
|Impact of STAG2 loss on DNA Damage and Immunobiology in Ewing sarcoma||University of Pittsburgh / Kelly Bailey, MD, PhD||Innovation Grants||2022||Pennsylvania|
|Molecular circuitry of fibrolamellar carcinoma||Massachusetts General Hospital / Nabeel Bardeesy, PhD||Innovation Grants||2022||Massachusetts|
|Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma||University of Massachusetts Amherst / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD||Innovation Grants||2022||Massachusetts|
|Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma||University of Massachusetts Chan Medical School / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD||Innovation Grants||2022||Massachusetts|
|Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy||University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD||Innovation Grants||2022||Wisconsin|
|Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia||Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD||Innovation Grants||2022||New York|
|Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia||The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD||Innovation Grants||2022||Maryland|
|Targeting CKLF as an Immunotherapeutic Approach to Treat MYCN-driven High-risk Neuroblastoma||Boston University / Hui Feng, Md, PhD||Innovation Grants||2022||Massachusetts|
|Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma||Dana-Farber Cancer Institute / Rani George, MD, PhD||Innovation Grants||2022||Massachusetts|